MGX (Metagenomi Therapeutics) FCF Margin %: -1,698.72% (As of Mar. 2026)


MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.19
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics FCF Margin %?

Metagenomi Therapeutics MGX -1.08% 10 FCF Margin % is -1,698.72% as of Mar. 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 960 Biotechnology companies, Metagenomi Therapeutics ranks worse than 68.65% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Metagenomi Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-21.20 Mil. Metagenomi Therapeutics's Revenue for the three months ended in Mar. 2026 was $1.25 Mil. Therefore, Metagenomi Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -1,698.72%.

As of today, Metagenomi Therapeutics's current FCF Yield % is -195.40%.

The historical rank and industry rank for Metagenomi Therapeutics's FCF Margin % or its related term are showing as below:

MGX' s FCF Margin % Range Over the Past 10 Years
Min: -391.99   Med: -214.53   Max: 8787.65
Current: -391.99

During the past 5 years, the highest FCF Margin % of Metagenomi Therapeutics was 8787.65%. The lowest was -391.99%. And the median was -214.53%.

MGX's FCF Margin % is ranked worse than
68.65% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs MGX: -391.99

Metagenomi Therapeutics FCF Margin % Related Terms

Metagenomi Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics FCF Margin % Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
8,787.65 91.55 -226.17 -214.53 -354.88

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -560.46 -251.12 -246.30 -604.22 -1,698.72

MGX vs HYPD, ATYR, ACTU: FCF Margin % Comparison

For the Biotechnology subindustry, Metagenomi Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Metagenomi Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Metagenomi Therapeutics's FCF Margin % falls into.


MGX
10GF Score
Metagenomi Therapeutics Inc MGX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Metagenomi Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-89.466/25.21
=-354.88 %

Metagenomi Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-21.2/1.248
=-1,698.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -1,698.72% mean?
Metagenomi Therapeutics (MGX) has a FCF Margin % of -1,698.72% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Metagenomi Therapeutics and its competitors. According to the industry distribution chart, Metagenomi Therapeutics ranks #659 out of 960 companies in the Biotechnology industry, placing it in the top 68.6%.
Is Metagenomi Therapeutics' FCF Margin % too high?
Metagenomi Therapeutics' current FCF Margin % is -1,698.72%. Based on the distribution chart, Metagenomi Therapeutics ranks #659 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' FCF Margin % compare to HYPD and ATYR?
According to the Biotechnology industry distribution chart, Metagenomi Therapeutics ranks #659 out of 960 companies for FCF Margin %. This places Metagenomi Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current FCF Margin % is -1,698.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current FCF Margin % of -1,698.72%. The current FCF Margin % is -1,698.72%. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current FCF Margin % is -1,698.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.19
Price